keyword
https://read.qxmd.com/read/38505589/case-report-dissolving-carotid-plaque-associated-to-lorlatinib-related-dyslipidemia
#1
Lukas Mayer-Suess, Michael Knoflach, Andreas Pircher, Stefan Kiechl, Christoph Schmidauer, Eva Hametner
We present a case with prolonged Lorlatinib-related dyslipidemia causing internal carotid artery stenosis, putting the patient at risk of cerebrovascular events. Through intensified lipid-lowering treatment and dose reduction of Lorlatinib, LDL-C levels decreased markedly. Surprisingly, the left sided internal carotid artery stenosis dissolved accordingly. Due to the high efficacy of the new selective tyrosine kinase inhibitors and resulting long-term treatment, it is essential to carefully follow-up and include drug specific side effect monitoring...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38496685/her3-overexpression-a-predictive-marker-for-poor-prognosis-in-advanced-alk-positive-non-small-cell-lung-cancer-treated-with-alk-inhibitors
#2
JOURNAL ARTICLE
Meejeong Kim, Hyun-Min Ju, Ji-Young Song, Josephina Sampson, Richard Bayliss, Jene Choi
BACKGROUND: Anaplastic lymphoma kinase (ALK)-targeted tyrosine kinase inhibitors (TKIs) improve patient survival; however, some patients develop ALK-TKI resistance with unidentified mechanisms. We investigated ErbB family and c-MET expression in patients with ALK-positive non-small cell lung cancer (NSCLC) to understand their roles in the ALK-TKI response. METHODS: We studied 72 patients with advanced ALK-positive NSCLC with EML4-ALK fusion variant subtyping and immunostaining for c-MET, EGFR, HER2, and HER3 on tissue specimens both pre- (primary) and post-treatment (secondary) with ALK-TKI...
February 29, 2024: Translational Lung Cancer Research
https://read.qxmd.com/read/38494766/-chinese-expert-consensus-on-iruplinalkib-for-the-treatment-of-locally-advanced-or-metastatic-alk-positive-non-small-cell-lung-cancer-2024-edition
#3
JOURNAL ARTICLE
(no author information available yet)
Anaplastic lymphoma kinase (ALK) fusion gene is one of the most common driver gene in non-small cell lung cancer (NSCLC). Epidemiological data showed that ALK gene fusion is detected in 9.06% of Chinese advanced NSCLC patients. ALK-tyrosine kinase inhibitors (TKIs) have become the standard treatment for advanced NSCLC patients with ALK gene fusion. Seven different ALK-TKIs have been approved by the National Medical Products Administration (NMPA) of China, including crizotinib, ceritinib, alectinib, ensartinib, brigatinib, lorlatinib, and iruplinalkib...
March 23, 2024: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://read.qxmd.com/read/38439810/real-world-study-of-safety-and-efficacy-of-lorlatinib-as-second-line-and-beyond-in-alk-rearranged-advanced-non-small-cell-lung-cancer-patients-in-india-a-multicentre-chart-review-study-roseland
#4
JOURNAL ARTICLE
Bivas Biswas, Nikhil S Ghadyalpatil, Shekar Patil, Amol Patel, Sandip Ganguly, Anvesh Rathore, Bhupesh Guleria, Cpalli Firdouse Tarannum, Joydeep Ghosh, Mary Sravani Kondapally, Ravi Thippeswamy, Shashidhara Haragadde Poppa Reddy, Somnath Roy
BACKGROUND: Lorlatinib, an anaplastic lymphoma kinase (ALK)-inhibitor, is approved as frontline as well as subsequent line of therapy in ALK-rearranged advanced non-small cell lung cancer (NSCLC). There is limited literature about safety and efficacy of lorlatinib in Indian patients. MATERIALS AND METHODS: This was a retrospective multicentre study on patients with ALK-rearranged advanced NSCLC received lorlatinib as second line and beyond between May 2017 and December 2021...
2024: Ecancermedicalscience
https://read.qxmd.com/read/38435286/cost-effectiveness-of-first-line-versus-second-line-use-of-brigatinib-followed-by-lorlatinib-in-patients-with-alk-positive-non-small-cell-lung-cancer
#5
JOURNAL ARTICLE
Wenjie Liu, Gengwei Huo, Peng Chen
BACKGROUND: The ALTA-1 L trial and EXP-3B arm of NCT01970865 trial found that both brigatinib and lorlatinib showed durable and robust responses in treating ALK-positive non-small cell lung cancer (NSCLC) patients. However, brigatinib and lorlatinib treatments are costly and need indefinite administration until the disease progression. Thus, it remains uncertain whether using brigatinib followed by lorlatinib before chemotherapy is cost-effective compared to reserving these two drugs until progression after chemotherapy...
2024: Frontiers in Public Health
https://read.qxmd.com/read/38434770/long-term-efficacy-and-safety-of-lorlatinib-in-japanese-patients-with-alk-positive-advanced-nsclc-a-brief-report-from-the-crown-study
#6
JOURNAL ARTICLE
Shunsuke Teraoka, Hidetoshi Hayashi, Yasushi Goto, Makoto Nishio, Shunichi Sugawara, Takao Inoue, Satoshi Oizumi, Shigeyuki Toyoizumi, Masakazu Matsumura, Rossella Messina, Terufumi Kato
INTRODUCTION: Lorlatinib was found to have improved efficacy versus crizotinib in the global phase 3 CROWN study (NCT03052608). Similar results were revealed for the Japanese population as for the overall population. We present results from the unplanned 3-year follow-up from the CROWN study in Japanese patients. METHODS: Patients were randomized to either lorlatinib 100 mg once daily (n = 25) or crizotinib 250 mg twice daily (n = 23). The primary end point was progression-free survival assessed by blinded independent central review...
March 2024: JTO clinical and research reports
https://read.qxmd.com/read/38433979/overcoming-central-%C3%AE-sheet-6-c%C3%AE-6-alk-mutation-l1256f-tp53-mutations-and-short-forms-of-eml4-alk-v3-b-and-v5a-b-splice-variants-are-the-unmet-need-that-a-re-imagined-5th-generation-5g-alk-tki-must-deliver
#7
JOURNAL ARTICLE
Alexandria T M Lee, Sai-Hong Ignatius Ou
Despite the development and approval of seven anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) spanning over three "generations" since the discovery of ALK fusion positive ( ALK+ ) non-small cell lung cancer (NSCLC), there remains intrinsic and acquired resistances to these approved TKIs. Currently, a fourth-generation (4G) ALK TKI, NVL-655, is being developed to attack some of the unmet needs such as compound resistance mutations in cis . However, EML4-ALK variant 3 and TP53 mutations are intrinsic genomic alterations that negatively modulate efficacy of ALK TKIs...
2024: Lung Cancer: Targets and Therapy
https://read.qxmd.com/read/38433235/crispr-cas9-edited-ros1%C3%A2-%C3%A2-non-small-cell-lung-cancer-cell-lines-highlight-differential-drug-sensitivity-in-2d-vs-3d-cultures-while-reflecting-established-resistance-profiles
#8
JOURNAL ARTICLE
Marc Terrones, Christophe Deben, Felicia Rodrigues-Fortes, Anne Schepers, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer
INTRODUCTION: The study of resistance-causing mutations in oncogene-driven tumors is fundamental to guide clinical decisions. Several point mutations affecting the ROS1 kinase domain have been identified in the clinical setting, but their impact requires further exploration, particularly in improved pre-clinical models. Given the scarcity of solid pre-clinical models to approach rare cancer subtypes like ROS1 + NSCLC, CRISPR/Cas9 technology allows the introduction of mutations in patient-derived cell lines for which resistant variants are difficult to obtain due to the low prevalence of cases within the clinical setting...
March 3, 2024: Journal of Translational Medicine
https://read.qxmd.com/read/38416709/mechanisms-of-resistance-to-tyrosine-kinase-inhibitors-in-ros1-fusion-positive-nonsmall-cell-lung-cancer
#9
JOURNAL ARTICLE
Xinmin Zhao, Xin Zhang, Hanlin Chen, Hairong Bao, Xianghua Wu, Huijie Wang, Hua Bao, Jiaohui Pang, Sha Wang, Jialei Wang
BACKGROUND: ROS1 fusion-positive (ROS1+) nonsmall cell lung cancer (NSCLC) patients are highly sensitive to tyrosine kinase inhibitor (TKI) treatments. However, acquired TKI resistance remains the major hurdle preventing patients from experiencing prolonged benefits. METHODS: 107 advanced or metastatic ROS1+ NSCLC patients who progressed on crizotinib and lorlatinib were recruited. Tissue and plasma samples were collected at baseline (N = 50), postcrizotinib (N = 91), and postlorlatinib (N = 21), which were all subject to the 139-gene targeted next-generation DNA sequencing...
February 28, 2024: Clinical Chemistry
https://read.qxmd.com/read/38406049/toxic-erythema-of-chemotherapy-vasculitic-eruption-with-malignant-intertrigo-characteristics-and-superimposed-infection-post-bevacizumab-initiation
#10
Kristin N Slater, Trevor Nessel, Francisca Kartono
Drug reactions are a known risk in combined anti-cancer therapy. Less commonly recognized risks of chemotherapies and targeted immunotherapies include toxic erythema of chemotherapy reactions. With the immunosuppressive quality of cancer combined with anti-cancer treatments, patients are also susceptible to increased infection. We report a rare case of combined targeted anti-cancer treatment with bevacizumab and lorlatinib, and an associated transformation of an eczematous process into a toxic erythema of chemotherapy vasculitic eruption, with combined malignant intertrigo characteristics and superimposed infection following the initiation of bevacizumab...
January 2024: Curēus
https://read.qxmd.com/read/38404995/non-bacterial-thrombotic-endocarditis-in-ros1-rearranged-lung-cancer-a-report-of-two-cases
#11
Jordi Recuero-Borau, Laura Masfarré, Nil Navarro, Pedro Rocha, Álvaro Taus, Edurne Arriola
BACKGROUND: Lung cancer is one of the tumor types with highest incidence of thromboembolic events (TE), especially adenocarcinoma subtype. ROS1 rearrangements confer higher risk of TE. Non-bacterial thrombotic endocarditis (NBTE) is a rare event, frequently diagnosed on autopsy. Clinical suspicion is key to reach the diagnosis and start early treatment of the underlying cause and anticoagulation in order to improve patients' outcomes. CASE DESCRIPTION: Here we present two cases of NBTE in patients with ROS1 -rearranged lung cancer with different clinical debuts...
January 31, 2024: Translational Lung Cancer Research
https://read.qxmd.com/read/38394779/an-infant-type-hemispheric-glioma-with-sox5-alk-a-novel-fusion
#12
JOURNAL ARTICLE
Chia Chin Tsai, Man-Hsu Huang, Chia-Lang Fang, Kevin Li-Chun Hsieh, Tsung-Han Hsieh, Wan-Ling Ho, Hsi Chang, Min-Lan Tsai, Yu-Chien Kao, James S Miser, Tai-Tong Wong, Min-Yu Su, Yen-Lin Liu
Infant-type hemispheric glioma (IHG) is a rare pediatric brain tumor with variable response to chemotherapy and radiotherapy. Molecular insights into IHG can be useful in identifying potentially active targeted therapy. A male fetus was found to have congenital hydrocephalus at the gestational age of 37 weeks. Fetal MRI showed a 2.6 × 2.0-cm tumor located at the frontal horn of the left lateral ventricle, involving the left basal nuclei and thalamus. Tumor biopsy at the age of 2 days revealed an IHG consisting of spindle tumor cells with strong expression of GFAP and ALK...
February 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38389874/kinase-inhibitor-macrocycles-a-perspective-on-limiting-conformational-flexibility-when-targeting-the-kinome-with-small-molecules
#13
REVIEW
Baku Acharya, Debasmita Saha, Daniel Armstrong, Baha'a Jabali, Maha Hanafi, Alan Herrera-Rueda, Naga Rajiv Lakkaniga, Brendan Frett
Methods utilized for drug discovery and development within the kinome have rapidly evolved since the approval of imatinib, the first small molecule kinase inhibitor. Macrocycles have received increasing interest as a technique to improve kinase inhibitor drug properties evident by the FDA approvals of lorlatinib, pacritinib, and repotrectinib. Compared to their acyclic counterparts, macrocycles can possess improved pharmacodynamic and pharmacokinetic properties. This review highlights clinical success stories when implementing macrocycles in kinase-based drug discovery and showcases that macrocyclization is a clinically validated drug discovery strategy when targeting the kinome...
February 21, 2024: RSC medicinal chemistry
https://read.qxmd.com/read/38381603/anaplastic-lymphoma-kinase-alk-inhibitors-show-activity-in-colorectal-cancer-with-alk-rearrangements-case-series-and-literature-review
#14
JOURNAL ARTICLE
Tingting Hu, Jinbo Zhan, Li Li, Yan He, Yun Lin, Jingru Wang, Haiming Yu, Jianping Xiong, Ziling Fang, Jun Deng, Shanshan Huang, Xiaojun Xiang
Anaplastic lymphoma kinase (ALK) rearrangement is a well-known driver oncogene detected in approximately 5% of non-small cell lung cancer. However, ALK rearrangement is much less frequent in other solid tumors outside the lungs, such as colorectal cancer (CRC); thus, the optimal management of CRC with ALK rearrangements has yet to be established. In this report, we describe 2 cases of ALK-positive CRC, both of which benefited from ALK tyrosine kinase inhibitor (ALK-TKI) therapy. Case 1 was a postoperative patient with poorly differentiated colon adenocarcinoma, who was diagnosed with metastatic relapse shortly after surgery...
February 21, 2024: Oncologist
https://read.qxmd.com/read/38360931/inflammation-related-molecular-signatures-involved-in-the-anticancer-activities-of-brigatinib-as-well-as-the-prognosis-of-eml4-alk-lung-adenocarcinoma-patient
#15
JOURNAL ARTICLE
Fu-Jing Ge, Xiao-Yang Dai, Yao Qiu, Xiang-Ning Liu, Chen-Ming Zeng, Xiao-Yuan Xu, Yi-Dan Chen, Hong Zhu, Qiao-Jun He, Ren-Hua Gai, Sheng-Lin Ma, Xue-Qin Chen, Bo Yang
Although ALK tyrosine kinase inhibitors (ALK-TKIs) have shown remarkable benefits in EML4-ALK positive NSCLC patients compared to conventional chemotherapy, the optimal sequence of ALK-TKIs treatment remains unclear due to the emergence of primary and acquired resistance and the lack of potential prognostic biomarkers. In this study, we systematically explored the validity of sequential ALK inhibitors (alectinib, lorlatinib, crizotinib, ceritinib and brigatinib) for a heavy-treated patient with EML4-ALK fusion via developing an in vitro and in vivo drug testing system based on patient-derived models...
February 15, 2024: Acta Pharmacologica Sinica
https://read.qxmd.com/read/38357093/lorlatinib-after-alectinib-induced-pneumonitis-a-case-report
#16
James A Fletcher, William J Mullally, Rahul Ladwa, Kenneth J O'Byrne
ALK gene rearrangements are detected in approximately 3% to 5% of NSCLC. ALK tyrosine kinase inhibitors, such as third-generation lorlatinib, have exhibited remarkable efficacy in ALK -rearranged NSCLC; however, they have been associated with a low incidence of treatment-limiting and potentially fatal drug-induced interstitial lung disease (ILD). There is concern that this may represent a class effect, a theory that is supported by a number of case reports. Because of clinical trial exclusion criteria, there are limited prospective data to guide decision-making after ALK tyrosine kinase inhibitors-induced ILD...
February 2024: JTO clinical and research reports
https://read.qxmd.com/read/38344482/inflammatory-myofibroblastic-tumor-with-rapid-recurrence-and-distant-metastasis-report-of-a-rare-case
#17
Dipti Kalita, Ruchi Rastogi, Gunmala Bhatnagar, Kunjahari Medhi, Sanjay K Pandey
Inflammatory myofibroblastic tumors (IMTs) are rare spindle cell tumors clinically, morphologically, and genetically heterogeneous, mimicking many other reactive and neoplastic lesions and creating great diagnostic problems. Although it is generally characterized by oncogene-derived proliferation of myofibroblasts in a background of polyclonal inflammatory cell infiltrates, morphological variations do occur requiring immunohistochemistry and molecular genetics to confirm the diagnosis. It encompasses a wide age range, and locations, mostly said to be of intermediate grade having a low risk of recurrence and metastasis...
January 2024: Curēus
https://read.qxmd.com/read/38344203/effective-treatment-of-advanced-lung-adenocarcinoma-with-paraneoplastic-leukemoid-reaction-with-lorlatinib-a-case-report
#18
Ruiqi Niu, Yiruo Zhang, Jingdan Pang, Qing Zhou, Yu Lei, Yingying Du
BACKGROUND: Lorlatinib is a new generation ALK kinase inhibitor. We describe a 52-year-old patient with ALK-positive advanced lung adenocarcinoma who achieved remission after multi-line therapy combined with paraneoplastic leukemoid reaction treated with Lorlatinib. CASE REPORT: A 52-year-old male patient was diagnosed with stage IV right lung adenocarcinoma, ALK: (+), previously received oral Crizotinib and Alectinib. Blood routine showed white blood cells abnormally elevated after disease progression, and maximum white blood cell count was 179...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38331773/identifying-optimal-alk-inhibitors-in-first-and-second-line-treatment-of-patients-with-advanced-alk-positive-non-small-cell-lung-cancer-a-systematic-review-and-network-meta-analysis
#19
JOURNAL ARTICLE
Mingye Zhao, Taihang Shao, Hanqiao Shao, Caicun Zhou, Wenxi Tang
OBJECTIVES: To compare the efficacy, safety and effects on quality of life of different ALK-inhibitors for global and Asian patients with advanced ALK-positive non-small-cell lung cancer (NSCLC). METHODS: The included RCTs were identified through a systematic search of PubMed, EMBASE, Cochrane Library, Clinical Trials.gov, and major cancer conferences. The assessment of progression-free survival (PFS), intracranial PFS, overall survival (OS), and patient-reported outcomes (PROs) was carried out using restricted mean survival time (RMST) model, fractional polynomial model and Royston-Parmar model...
February 8, 2024: BMC Cancer
https://read.qxmd.com/read/38317359/-china-expert-recommendations-on-anaplastic-lymphoma-kinase-tyrosine-kinase-inhibitors-treatment-for-advanced-non-small-cell-lung-cancer-2024-edition
#20
JOURNAL ARTICLE
(no author information available yet)
Anaplastic lymphoma kinase (ALK) fusion represents one of pivotal driver genes within the realm of non-small cell lung cancer (NSCLC). ALK-tyrosine kinase inhibitors (ALK-TKI) have demonstrated remarkable therapeutic efficacy for patients afflicted with ALK-positive NSCLC. As of June 27, 2023, seven ALK-TKI, including crizotinib, ceritinib, alectinib, ensartinib, brigatinib, lorlatinib, and iruplinalkib, have garnered approval from the China National Medical Products Administration (NMPA)(ranking according to the approval time for marketing by NMPA), providing individualized treatment modalities for ALK-positive NSCLC patients...
February 20, 2024: Zhonghua Yi Xue za Zhi [Chinese medical journal]
keyword
keyword
96146
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.